Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence

Duke University

Status and phase

Completed

Phase 4

Conditions

Schizophrenia

Schizoaffective Disorder

Treatments

Drug: Depot Risperidone Microsphere (Consta)

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00215579

5631

RIS-SCH-421 (Other Identifier)

Details and patient eligibility

About

As many as 75 percent of patients with schizophrenia have difficulty taking their oral medication on a regular basis. This may lead to worsening of symptoms. Clinicians commonly respond to these problems by adding adjunctive medications, despite the absence of systematic studies that support such practices. It is possible, however, that in many of these cases, the unstable course and/or unsatisfactory treatment response reflects incomplete adherence with the originally prescribed oral antipsychotic, rather than a need for adjunctive medications. This study will examine whether switching patients who demonstrate an unstable course and/or an unsatisfactory clinical response to a long-acting injectable preparation as the primary antipsychotic may enhance medication adherence and improve outcomes.

Enrollment

64 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Eligible patients will be male or female
Between 18-65 years of age and will meet DSM-IV criteria for schizophrenia or schizoaffective disorder.
The subject must have, in their physicians opinion, an unstable course and must have been treated with an oral antipsychotic.

Exclusion criteria

Pregnant and breast feeding females will be excluded.
Because fluoxetine is known to change the plasma level of CONSTA, subjects taking fluoxetine within two weeks of starting the study will be excluded.
Patients who are known to have a hypersensitivity to oral Risperdal will be excluded.